Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lower Urinary Tract Symptoms (LUTS) Clear all
Completed Phase 2 Interventional Results available

Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

NCT00507455
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Interventions
solifenacin succinate, tamsulosin hydrochloride, Placebo to solifenacin, Placebo to tamsulosin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Homewood, Alabama • La Mesa, California • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Jul 21, 2026, 7:29 PM EDT
Recruiting No phase listed Observational

BPH Global Registry

NCT05543200
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Not listed
Lead sponsor
Société Internationale d'Urologie
Other
Eligibility
18 Years and older · Male only
Enrollment
7,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 21, 2026, 7:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Validation of Bladder Health Instrument for Evaluation in Women

NCT04016298
View directory record Official record
Conditions
Lower Urinary Tract Symptoms
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
1,222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Jul 21, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

NCT00947882
View directory record Official record
Conditions
Lower Urinary Tract Symptoms (LUTS)
Interventions
Placebo, Degarelix 10 mg, Degarelix 20 mg, Degarelix 30 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
50 Years and older · Male only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Homewood, Alabama • Mobile, Alabama • Newport Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Jul 21, 2026, 7:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

RISE FOR HEALTH Study

NCT05365971
View directory record Official record
Conditions
Lower Urinary Tract Symptoms
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
3,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
9
States / cities
Birmingham, Alabama • San Diego, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Jul 21, 2026, 7:29 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT02757768
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Overactive Bladder
Interventions
Mirabegron, Placebo, Tamsulosin Hydrochloride
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Jul 21, 2026, 7:29 PM EDT
Recruiting No phase listed Observational

Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia

NCT07016620
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Transperineal Laser Ablation (TPLA)
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older · Male only
Enrollment
20 participants
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 21, 2026, 7:29 PM EDT
Completed Phase 2 Interventional

A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT02326454
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
talaporfin sodium, Saline, Drug Activator 100 J/cm, Drug Activator 200 J/cm
Drug · Device
Lead sponsor
Light Sciences Oncology
Industry
Eligibility
40 Years and older · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Anniston, Alabama • Huntsville, Alabama • Anchorage, Alaska + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Jul 21, 2026, 7:29 PM EDT
Recruiting No phase listed Observational

Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms

NCT07377929
View directory record Official record
Conditions
Benign Prostatic Hypertrophy (BPH), Lower Urinary Track Symptoms
Interventions
Survey using a questionnaire.
Other
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 21, 2026, 7:29 PM EDT
Completed Not applicable Interventional Results available

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II

NCT03123250
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Aquablation
Device
Lead sponsor
PROCEPT BioRobotics
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jul 21, 2026, 7:29 PM EDT
Recruiting Not applicable Interventional

HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer

NCT03802851
View directory record Official record
Conditions
Prostate Cancer, Lower Urinary Tract Symptoms
Interventions
Holmium Laser Enucleation of Prostate (HoLEP)
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 21, 2026, 7:29 PM EDT
Completed Phase 2 Interventional

Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

NCT01939184
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
WC3055, Placebo
Drug · Other
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years and older · Male only
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
95
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 80 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Jul 21, 2026, 7:29 PM EDT
Withdrawn Not applicable Interventional

Prostatic Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)

NCT04563221
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Prostatic artery embolization
Device
Lead sponsor
Andrew Picel
Other
Eligibility
45 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Jul 21, 2026, 7:29 PM EDT
Completed No phase listed Observational

Deep Brain Stimulation in Patients With LUTS

NCT03202251
View directory record Official record
Conditions
Bladder Dysfunction, Neurogenic Bladder
Interventions
It's is a cohort
Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jul 21, 2026, 7:29 PM EDT
Completed Phase 3 Interventional

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)

NCT01846793
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, BPH, Lower Urinary Tract Symptoms (LUTS), LUTS
Interventions
NX-1207
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years and older · Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Laguna Beach, California • San Diego, California • Aventura, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Jul 21, 2026, 7:29 PM EDT
Terminated Phase 2 Interventional

Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)

NCT00743184
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS)
Interventions
ozarelix, Placebo
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
50 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Jul 21, 2026, 7:29 PM EDT
Completed Not applicable Interventional

Effects of LycoComfort™ Supplementation on Symptoms Associated With Lower Urinary Tract Symptoms (LUTS)

NCT03772808
View directory record Official record
Conditions
BPH, Lower Urinary Tract Symptoms
Interventions
Lycocomfort
Dietary Supplement
Lead sponsor
LycoRed Ltd.
Industry
Eligibility
40 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Jul 21, 2026, 7:29 PM EDT
Terminated Phase 2 Interventional

Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome

NCT06351683
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Overactive Bladder Syndrome
Interventions
MitoQ (mitoquinol mesylate), Placebo
Drug · Other
Lead sponsor
Iman Al-Naggar, PhD
Other
Eligibility
50 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 21, 2026, 7:29 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Establishing Normative Urodynamics Parameters for the Glean Urodynamics System in Healthy Adults

NCT07485205
View directory record Official record
Conditions
Lower Urinary Tract Symptoms (LUTS)
Interventions
Glean Urodynamics System
Device
Lead sponsor
Bright Uro
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Tucson, Arizona • Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 21, 2026, 7:29 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Cyclic Versus Continuous Sacral Neuromodulation for LUTS

NCT06170450
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Cyclic SNM, Continuous SNM
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
3
States / cities
Louisville, Kentucky • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jul 21, 2026, 7:29 PM EDT
Not yet recruiting No phase listed Observational

Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry

NCT07538622
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia)
Interventions
Zenflow Spring System
Device
Lead sponsor
Zenflow, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
La Mesa, California • Tampa, Florida • Winter Garden, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 21, 2026, 7:29 PM EDT
Terminated Phase 4 Interventional Results available

Tetra-NIRS Clinical Study

NCT00871975
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Overactive Bladder
Interventions
Urodynamics + TETRA - NIRS
Device
Lead sponsor
Laborie Medical Technologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Jul 21, 2026, 7:29 PM EDT
Completed Not applicable Interventional Results available

Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT02930889
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Prostate Artery Embolization
Device
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Jul 21, 2026, 7:29 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

ProVee Urethral Expander System IDE Study (ProVIDE)

NCT05186740
View directory record Official record
Conditions
BPH With Symptomatic Lower Urinary Tract Symptoms
Interventions
ProVee Urethral Expander System, Urethral Access Sheath
Device · Procedure
Lead sponsor
ProVerum Medical
Industry
Eligibility
45 Years and older · Male only
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
15
States / cities
Sacramento, California • Hialeah, Florida • Palm Coast, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 21, 2026, 7:29 PM EDT